Cancers harboring K171-mutated IKKβ are likely to also exhibit activated STAT3 and p44/42 MAPK (Erk1/2), suggesting the possibility of using MAPK (Erk1/2) and JAK inhibitors, or specific ubiquitination inhibitors. Here, MAPK3 is linked to cancer.